%0 Journal Article
%T Real-life management of psoriasis with biological agents during pregnancy.
%A Tran C
%A Mahé E
%A Beylot-Barry M
%A Jullien D
%A Richard MA
%A Fougerousse AC
%A Bouznad A
%A Bulai Livideanu C
%A Brun A
%A Amelot F
%A Maccari F
%A Aubin F
%A Benhadou F
%A Paul C
%J Ann Dermatol Venereol
%V 151
%N 2
%D 2024 Jun 29
%M 38554588
%F 0.934
%R 10.1016/j.annder.2024.103254
%X BACKGROUND: French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this study was to evaluate the real-life practice of dermatologists in the management of pregnant women with psoriasis previously treated with biologic agents. We wished to assess the level of practitioner adherence to the relevant SmPCs.
METHODS: We conducted a study in collaboration with GRPso and Resopso. A computerized questionnaire was completed by the practitioners. We performed descriptive statistics and studied the profile of the practitioners, their level of confidence with continuation of biological agents during pregnancy, and their reported practices on the use of biological agents in pregnancy. Statistical analyses were performed using XLSTAT. A p-value of less than 0.05 was considered significant.
RESULTS: A total of 63 dermatologists (women: 71%; mean age 43.8 years) participated in this study, the majority of whom were hospital-based (87%). Recommendations were followed by 36.5% of practitioners, while 44% reported discontinuing biologic agents on diagnosis of pregnancy, and 20.5% reported using these agents during pregnancy. Among dermatologists with more than ten years of experience, 19% reported following the SmPC. Among dermatologists with a patient base >200 (patients treated with biologic agents for psoriasis), 19% reported following the SmPC compared to 54% of practitioners with less than 50 patients. The mean age of dermatologists following the SmPC was 41 years vs. 47 years for those not following the SmPC.
CONCLUSIONS: The majority of practitioners do not follow recommendations on discontinuation of biologic agents before the planning of pregnancy by patients.